PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
7 July 2025
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
29 January 2025
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
27 January 2025
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
27 January 2025
Opdivo and Yervoy succeed again, but the US path remains unclear.
23 January 2025
The company might need something better to replace its ageing blockbuster.
22 January 2025
Poor efficacy clouds prospects for the company's "improved" Yervoy.